Completed PHASE1 INTERVENTIONAL 2-arm NCT04811196

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas

Sponsor: University Health Network, Toronto

Conditions Endometrial Stromal Sarcoma Leiomyosarcoma Malignant Peripheral Nerve Sheath Tumor (MPNST) Soft Tissue Sarcoma

Interventions Selinexor

Updated 7 times since 2021 Last updated: May 22, 2025 Started: Mar 29, 2021 Primary completion: May 15, 2025 Completion: May 15, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Endometrial Stromal Sarcoma and Leiomyosarcoma and is currently completed. University Health Network, Toronto leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2024 — Jun 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2023 — Apr 2024 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

May 2022 — Sep 2023 [monthly]

Recruiting PHASE1
Apr 2021 — May 2022 [monthly]

Recruiting PHASE1

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada